Skip to main content

Deal Alert: Fidelity Growth Partners India Leads an INR 400Crore(US$ 75 million) Investment Round in Trivitron Healthcare Private Limited

From the Press Release:

Trivitron Healthcare Private Limited (Trivitron) announced today that Fidelity Growth Partners India (FGPI) hasanchored a round of investmentof approximately INR 400crores (US$ 75 million).This investment also provides partial exits for ePlanet Ventures and Headland Capital, who have been invested in Trivitron since 2007. 

For the past fifteen years, Trivitronhas been India’s largest exclusive pan India wholesale distributor and after-sales support provider of medical equipment and devices. Its areas of expertise include imaging, lab diagnostics, cardiology, critical care,renal care, operating room and ophthalmology equipment. Trivitron is the partner of choice for anyforeign manufacturer looking to enter the country on account of its strong reputation and track record, national sales-and-service network and robust logistics infrastructure. 

Over the past few years, subsidiaries and joint ventures of Trivitron havebeen steadily laying the foundations for manufacturing medical equipment. Trivitron Medical Technology Park, a 25-acre state-of-the-art manufacturing facility in Chennai, was established in 2009 to house over 15 different medical technology manufacturing facilities of Trivitron’s subsidiaries and joint ventures;Trivitron’s joint ventures with Hitachi-Aloka (Japan) for manufacturing ultrasound equipment and with Biosystems (Spain) for lab diagnostics reagents are already operational.The company has recently set up centres of innovationfor biomedical equipment in collaboration with the Indian Institute of Technology (IIT), Chennai and under the leadership of its Director (R&D), Prof. Bhuvaneshwar, a wellrecognized innovator in this area. 

With the new fund infusion into the company, Trivitron aims to become a global player in the imaging and labdiagnosticssegments through organic growth as well as through acquisition of companies and technologies in Europe and the United States. The funds will be used to increaseTrivitron’s shareholding in Kiran Medical Systems, an international player in imaging accessories, expanding operations at Trivitron Medical Technology Park, and enhancing the company’s distribution operations in South East Asia, Middle East and Africa. 

Trivitron was founded in 1997 by Dr. G.S.K. Velu after his stint as the Country Head for Chiron Diagnostics, before embarking on a successful entrepreneurial journey. In addition to Trivitron, Dr. Velu has co-founded and built the country’s leading path lab chain, Metropolis Healthcare, as well as Medfort, a chain of single specialty, eye-care and diabetes-care hospitals. He has also co-founded a joint venture with the Apollo Hospitals Group for dental clinics(Apollo White) and dialysis centres (Apollo Dialysis). 

Commenting on the transaction, Mr. Raj Dugar, Senior Managing Director at FIL Capital Advisors (India) Private Limited, the private equity advisory arm for FGPI, said, "We are very excited to partner with Dr. Velu and Trivitron. Trivitron has a presence in both value and premium segments, and offers an excellent portfolio of products across India. The medical equipment sector in the country is still nascent and dominated by imports. We believe that India will follow the same evolution trajectory as other emerging markets like China where large, indigenous manufacturers of medical equipment have emerged over the past decade. Trivitron is well positioned to capitalize on this trend with its unparalleled distribution and service infrastructure that is difficult to replicate. High quality manufacturing efforts of Trivitron’ssubsidiaries and joint ventureswill allow Trivitron to expand its product portfolio to all segments of the market.” 

Dr. Velu said, “We are excited to have Fidelity as new investors and board members in Trivitron. Fidelity with its vast knowledge in the medical devices space in China, USA, and Europe will be able to add substantial value to Trivitron in becoming a global player in the imaging and lab diagnostics segments.Fidelity’s long-standing experience in China would also help us in making in-roads in the value segment.I am certain that Fidelity’s guidance would be invaluable in helping Trivitron implement its strong growth plan.”

Trivitron aims to close FY2012-13 with pro-forma gross revenues in excess of INR 700 crores through organic and inorganic routes enabled through this investment round. 

Kotak Mahindra Capital Company (KMCC), the investment banking arm of Kotak Mahindra Bank, was the exclusive advisor to Trivitron on the transaction. Amarchand &Mangaldas& Suresh A. Shroff& Co. acted as the company’s legal counsel. 

About Fidelity Growth Partners 

India Fidelity Growth Partners India (FGPI) is the India-focused private equity arm of Fidelity Worldwide Investment, focused on cross-sector growth capital investing. FGPI seeks to invest in high-quality, high-growth companies in India across a broad range of sectors with typical investment sizes ranging from $10 million to $50 million. FGPI is committed to making the companies it invests in leaders in their industries through access to patient capital with a long term investment mindset, a powerful network of resources and a team of investment professionals with a proven track record of success. Fidelity, Fidelity Worldwide Investment and Fidelity Growth Partners India are trademarks of FIL Limited.

Media contact person: 
Mr Arijit Sengupta
Direct: +91 22 6655 4057
Mob: +91 98203 40485
Email: arijit.sengupta@fil.com 

About Trivitron Healthcare Private Limited 

Established in the year 1997, Trivitron is the largest Indian multinational in medical technology with group revenues of approx.INR500 crores in FY2011-12. Headquartered in Chennai, Trivitron’s presencein India spans 20 offices, with 10 offices in other international locations including South Asia, South East Asia, Middle East and Africa. The company has over 1000 employees. Trivitron offers a value chain of end-to-end solutions in medical technology. Trivitron’s aim is to become the most admired global medical technology player through innovation, comprehensive product solutions and world class customer service and support. For further information logon to www.trivitron.com.

Media contact person
AasiyaShaikh
Mobile: +91 9833503994
Email:aasiya.shaikh@adfactorspr.com 

About KotakMahindra Capital Company Limited (Kotak Investment Banking)  

Kotak Mahindra Capital Company Limited (Kotak Investment Banking) is a leading full-service investment bank in India offering the complete range of capital market and advisory solutions to leading Indian and multinational corporations across diverse sectors. Our services include Equity and Debt Capital Market Issuances, M&A Advisory, Private Equity Advisory, Structured Finance Services and Infrastructure Advisory & Fund Mobilization. KMCC is a subsidiary of Kotak Mahindra Bank Limited, one of India's leading banking and financial services organizations with a consolidated net worth of Rs 13,943crore (approx US$ 2.6 billion) as on September 30, 2012. 

For more information, please visit http://investmentbank.kotak.com/ 

Media contact person
Phiroza Choksi 
Kotak Investment Banking
Mobile: +91 9820363681 
Email:phiroza.choksi@kotak.com

Popular posts from this blog

PE-VC investments in Q2'23 decline 33% to $9.9 Billion

Private Equity-Venture Capital (PE-VC) investments in India during the quarter ended June 2023 (Q2'23), at $9.85 Billion across 182 deals, registered a 33% decrease compared to the same period in 2022 (which saw $14.6 Billion being invested across 371 deals). The investment amount however rose 74% compared to the immediate previous quarter (which saw $5.7 Billion being invested across 181 deals), shows data from  Venture Intelligence , a research service focused on private company financials, transactions, and their valuations. The PE-VC investment figures for the first 6 months of 2023 - at $15.5 Billion (across 363 deals) - was 50% lower compared to the same period in 2022 (which saw $31 Billion being invested across 800 deals). Q2’23 witnessed 19 mega deals ($100 M+

Chiratae, Speciale and Stride Ventures win APEX'24 Venture Capital Awards

Chiratae Ventures, Speciale Invest and Stride Ventures were awarded as among the leading Venture Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) VC Investor of the Year Chiratae Ventures received the Venture Capital Investor of the Year 2023 Award on the back of 10 part exits totaling $178 million via Secondary Sales during the year. Its exits included those from retail unicorn Lenskart, SaaS Startup Pixis and baby pr

Blackstone, MO Alts and InvAscent win APEX'24 Private Equity Awards

Press Release Blackstone, MO Alternates (formerly Motilal Oswal PE) and InvAscent were awarded as among the leading Private Equity and Growth Capital investors in India for 2023 as part of Venture Intelligence APEX‘24 Private Equity & Venture Capital awards event in Mumbai.  The Venture Intelligence “Awards for Private Equity Excellence” (APEX) is dedicated to celebrating the best that the Indian Private Equity & Venture Capital industry has to offer. The APEX Awardees are selected based on both Self Nomination by the participating PE-VC firms and "crowd sourced" voting from the Limited Partner, PE-VC and advisory communities. (The main criteria are Return Track Record, New Fund Raises & Follow-on Funding Rounds for Portfolio Companies) PE Investor of the Year Blackstone received the Private Equity Investor of the Year 2023 Award on the back of strong complete exits during the year: from Sona Comstar and IBS Software. Ganesh Mani and Amit Dalmia, Senior Managing D

Avendus tops League Table for Transaction Advisors to PE deals in Q1'23

Aeka Advisors and Ambit claim the No.2 & 3 slot Avendus topped the Venture Intelligence League Table for Transaction Advisor to Private Equity Transactions for Q1 2023 advising 5 deals worth $808 million. Aeka Advisors stood second having advised 3 deals worth $228 million. Ambit followed with 4 deals worth $160 million. Ernst & Young ($114 million across 4 deals) and o3 Capital ($80 million across 2 deals) completed the top five for Q1 2023. Avendus acted as advisor to ADIA’s $500 million investment in omnichannel eyewear retailer Lenskart . Aeka Advisors acted as advisor to Kreditbee’s $160 million fundraise from Advent International, Mitsubishi UFJ Financial Group (MUFG) and existing investors. Ambit advised the $104 million fundraise of Freshtohome from Mount Judi Ventures, Iron Pillar, Amazon and others. The  Venture Intelligence League Tables , the first such initiative exclusively tracking transactions involving India-based companies, are based on the value of PE

PE-VC investments fall 38% in 2023 to below $30 B

The value of investments by Private Equity - Venture Capital (PE-VC) firms in India fell by 38% to less than $30 Billion in 2023. PE-VC firms invested $29.7 Billion (across 756 deals) in Indian companies in 2023, compared to $47.6 Billion (across 1,362 deals) in the previous year, reports Venture Intelligenc e, a research service focused on private company financials, transactions, and their valuations. (Note: These figures exclude PE investments in Real Estate).                                                                                                                                                                      2023 witnessed 67 mega deals ($100 M+ rounds) worth $21.2 Billion, compared to 112 such investments worth $31.8 Billion in 2022. The $2.4 Billion investment in Manipal Hospitals by Temasek (which gained majority control) and TPG Capital was the largest PE-VC investment in 2023. This was followed by the $1.35 Billion buyout of education loans focused HDFC Credila